Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Cash from Financing Activities (2016 - 2025)

Spyre Therapeutics' Cash from Financing Activities history spans 11 years, with the latest figure at $312.8 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 38.66% year-over-year to $312.8 million; the TTM value through Dec 2025 reached $309.0 million, down 24.79%, while the annual FY2025 figure was $309.0 million, 24.79% down from the prior year.
  • Cash from Financing Activities reached $312.8 million in Q4 2025 per SYRE's latest filing, up from -$4.6 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $312.8 million in Q4 2025 to a low of -$12.5 million in Q3 2023.
  • Average Cash from Financing Activities over 5 years is $56.3 million, with a median of $361000.0 recorded in 2021.
  • The largest YoY upside for Cash from Financing Activities was 2045175.0% in 2023 against a maximum downside of 9539.23% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $80000.0 in 2021, then tumbled by 110.0% to -$8000.0 in 2022, then surged by 2045175.0% to $163.6 million in 2023, then skyrocketed by 37.89% to $225.6 million in 2024, then soared by 38.66% to $312.8 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Cash from Financing Activities are $312.8 million (Q4 2025), -$4.6 million (Q3 2025), and $731000.0 (Q2 2025).